Aging-related immune remodeling in ovarian cancer: endocrine cues, cellular senescence, and tumor–immune crosstalk
Abstract
Ovarian cancer is diagnosed predominantly after menopause, but chronological age, reproductive aging, cellular senescence, immunosenescence, and treatment-related immune dysfunction are frequently conflated. This overlap obscures whether immune phenotypes arise from aging, tumor histotype, therapy, or tumor-derived signals and limits the interpretation of age-associated biomarkers and treatment studies. This narrative review critically evaluates how menopause-associated endocrine remodeling, stromal and cellular senescence, senescence-associated secretory phenotype factors, and IL-6, CXCL8, TNF-α, and IL-1β signaling may interact with the ovarian-cancer immune microenvironment. Histotype-defining genomic pathways, including TP53 alteration, homologous-recombination deficiency, and KRAS–MAPK signaling, are separated from mechanisms plausibly modified by aging. Evidence is interpreted according to four contexts: human ovarian cancer, non-malignant human ovary or pelvic tissue, ovarian cell and animal models, and indirect studies from other cancers or organs; age-resolved findings are considered separately. Human evidence supports marked heterogeneity in immune infiltration, T-cell dysfunction, suppressive myeloid programs, and cytokine signaling, but direct age-resolved clinical evidence remains limited. Tumor-driven immune escape, therapy-induced senescence, and systemic immunosenescence can generate overlapping phenotypes and require explicit separation in study design and interpretation. This review highlights an evidence framework based on histotype, tissue compartment, treatment exposure, functional age, and longitudinal sampling. Progress requires prospective cohorts that include older and frail adults and jointly assess tumor biology, immune state, treatment toxicity, and clinical outcome.
Related
- Metabolic-Epigenetic Coupling in Cellular Senescence: In Silico Cristae Remodeling Depletes Alpha-Ketoglutarate to Drive KDM4/6 Inhibition and SASP Amplification
- TRPM2-mediated Ca2+ entry drives cellular senescence to irradiation-induced salivary gland dysfunction
- Soluble pathogenic tau transmission to astrocytes drives acute oxidative damage, cellular senescence, and neurovascular uncoupling in a model of Alzheimers tauopathy
- Galectin-3 as a Candidate Marker of Endocrine-modulatorassociated Endometrial Remodeling During Breast Cancer Endocrine Therapy
- Senescence-induced cellular reprogramming drives cnidarian whole-body regeneration
BibTeX
@article{wang2026agingrelated,
title = {{Aging-related immune remodeling in ovarian cancer: endocrine cues, cellular senescence, and tumor–immune crosstalk}},
author = {Junyi Wang and Xinrui Yang and Weidong Huang and Lijie Xia},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2005508},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2005508},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Aging-related immune remodeling in ovarian cancer: endocrine cues, cellular senescence, and tumor–immune crosstalk
AU - Junyi Wang
AU - Xinrui Yang
AU - Weidong Huang
AU - Lijie Xia
PY - 2026
DA - 2026/11/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2005508
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2005508
AB - Ovarian cancer is diagnosed predominantly after menopause, but chronological age, reproductive aging, cellular senescence, immunosenescence, and treatment-related immune dysfunction are frequently conflated. This overlap obscures whether immune phenotypes arise from aging, tumor histotype, therapy, or tumor-derived signals and limits the interpretation of age-associated biomarkers and treatment studies. This narrative review critically evaluates how menopause-associated endocrine remodeling, stromal and cellular senescence, senescence-associated secretory phenotype factors, and IL-6, CXCL8, TNF-α, and IL-1β signaling may interact with the ovarian-cancer immune microenvironment. Histotype-defining genomic pathways, including TP53 alteration, homologous-recombination deficiency, and KRAS–MAPK signaling, are separated from mechanisms plausibly modified by aging. Evidence is interpreted according to four contexts: human ovarian cancer, non-malignant human ovary or pelvic tissue, ovarian cell and animal models, and indirect studies from other cancers or organs; age-resolved findings are considered separately. Human evidence supports marked heterogeneity in immune infiltration, T-cell dysfunction, suppressive myeloid programs, and cytokine signaling, but direct age-resolved clinical evidence remains limited. Tumor-driven immune escape, therapy-induced senescence, and systemic immunosenescence can generate overlapping phenotypes and require explicit separation in study design and interpretation. This review highlights an evidence framework based on histotype, tissue compartment, treatment exposure, functional age, and longitudinal sampling. Progress requires prospective cohorts that include older and frail adults and jointly assess tumor biology, immune state, treatment toxicity, and clinical outcome.
SN - 1664-3224
ER -